Skip to content

Sleep Position Device Versus Continuous Positive Airway Pressure in Mild to Moderate Central Sleep Apnea A Randomized Trial

Sleep Position Device Versus Continuous Positive Airway Pressure in Mild to Moderate Central Sleep Apnea A Randomized Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20065
Enrollment
200
Registered
2020-02-03
Start date
2020-02-27
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central positional sleep apnea syndrome

Interventions

Participants are assigned to either sleep position device (Night-Balance, Philips, The Netherlands) or CPAP (standard of care arm).

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Patients with central positional sleep apnoea are included in the study. 2. Apnoehypopneuindex = 5 AND = 30. 3. Patient age = 18. Central sleep apnoea is defined as: AHI = 5 with 50% or more of events occurring without any respiratory effort. And associated with symptoms of either excessive sleepiness or disrupted sleep. Positional sleep apnoea is defined as having a supine AHI=2x AHI non-supine with =10% and = 90% supine sleep

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. chronic respiratory insufficiency (paCO2 > 6kPA) 2. BMI = 30 3. Left sided valvular heart disease > mild 4. Patients with symptomatic heartfailure (AHA stadium C) 5. Night or rotating shift work 6. Active psychiatric disease 7. Seizure disorder 8. Medication use for sleeping disorders 9. Previous treatment with CPAP or sleep position device 10. Simultaneous other OSAS treatments 11. Pregnancy 12. Coexistent non-respiratory sleep disorders (e.g. insomnia, periodic limb movement disorder, narcolepsy) that would influence functional sleep assessment

Design outcomes

Primary

MeasureTime frame
AHI (apnea-hypopneas/hour) at 3 months and at 12 months will be compared to baseline. Succesfull treatment is defined as a reduction in AHI to < 5 events per hour at 3 months. Or either a 50% reduction in baseline AHI or a = 10 decrease in AHI combined with improvement in ESS (= 2 points). The proportion of patients reaching succesfull treatment in both treatment arms will be compared using Fisher’s exact test. Relative risk of succesfull treatment between both treatment arms will be calculated and 95% Confidence interval of the risk difference.

Secondary

MeasureTime frame
total central AI, total central AHI, AHI supine , AHI non supine, supine central AHI, non-supine central AHI, ESS, total sleep time supine, total sleep time non-supine.Compliance is measured according to digital use readings from Night-Balance sleep position device and CPAP machine, respectively, at 3 and 12 months follow-up.

Contacts

Public Contactwouter jacobs

martini ziekenhuis

w.jacobs@mzh.nl0620767110

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)